Payment overview · 2025
General Payments
$185.11
8 reported records · 5 companies
Healthcare provider profile · identity verified
Alfredo Reyes Dosdos, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTIS, FL · NPI 1427004548
Verified facts
What the public records show
CMS Open Payments records show Alfredo Reyes Dosdos, MD received $185.11 in general payments during 2025 across 8 reported records.
Amgen Inc. accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.95 | 40.0% | 4 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $48.67 | 26.3% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $23.19 | 12.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.59 | 12.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.71 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $185.11 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $73.95 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $73.95 | 4 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $48.67 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 687 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 633 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 447 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 439 | 131 |
| Alprazolam | Alprazolam | 405 | 105 |
| Losartan Potassium | Losartan Potassium | 405 | 120 |
| Lisinopril | Lisinopril | 369 | 104 |
| Metformin Hcl | Metformin Hcl | 283 | 78 |
| Zolpidem Tartrate | Zolpidem Tartrate | 239 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 62 |
| Ezetimibe | Ezetimibe | 177 | 63 |
| Azithromycin | Azithromycin | 176 | 149 |
| Pravastatin Sodium | Pravastatin Sodium | 170 | 58 |
| Simvastatin | Simvastatin | 165 | 45 |
| Omeprazole | Omeprazole | 164 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 52 |
| Sertraline Hcl | Sertraline Hcl | 155 | 48 |
| Montelukast Sodium | Montelukast Sodium | 146 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 50 |
| Temazepam | Temazepam | 136 | 22 |
| Glimepiride | Glimepiride | 128 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 45 |
| Nifedipine Er | Nifedipine | 125 | 39 |
| Carvedilol | Carvedilol | 119 | 34 |
| Atenolol | Atenolol | 109 | 33 |
| Gabapentin | Gabapentin | 99 | 26 |
| Allopurinol | Allopurinol | 93 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 30 |
| Famotidine | Famotidine | 80 | 32 |
| Finasteride | Finasteride | 77 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 23 |
| Methylprednisolone | Methylprednisolone | 77 | 61 |
| Ozempic | Semaglutide | 77 | 16 |
| Tramadol Hcl | Tramadol Hcl | 73 | 24 |
| Eszopiclone | Eszopiclone | 72 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 21 |
| Trazodone Hcl | Trazodone Hcl | 70 | 27 |
| Eliquis | Apixaban | 69 | 19 |
| Synthroid | Levothyroxine Sodium | 65 | 18 |
| Glipizide | Glipizide | 64 | 17 |
| Lorazepam | Lorazepam | 63 | 12 |
| Lovastatin | Lovastatin | 63 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 21 |
| Alendronate Sodium | Alendronate Sodium | 51 | 19 |
| Furosemide | Furosemide | 51 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 15 |
| Ibuprofen | Ibuprofen | 51 | 25 |
| Clonazepam | Clonazepam | 49 | 11 |
| Meloxicam | Meloxicam | 48 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 15 |
| Bupropion Xl | Bupropion Hcl | 47 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 13 |
| Glipizide Er | Glipizide | 45 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 12 |
| Prednisone | Prednisone | 41 | 20 |
| Diazepam | Diazepam | 40 | 17 |
| Enalapril Maleate | Enalapril Maleate | 40 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Jardiance | Empagliflozin | 37 | 13 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 15 |
| Valsartan | Valsartan | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 17 |
| Amoxicillin | Amoxicillin | 28 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 18 |
| Meclizine Hcl | Meclizine Hcl | 25 | 12 |
| Potassium Chloride | Potassium Chloride | 25 | 13 |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 21 |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Digoxin | Digoxin | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $185.11 · 8 records | Amgen Inc. | Dexcom G6 Transmitter, Integra, Integra Dermal Regeneration Template, OTEZLA, Ozempic, PRIMATRIX, REPATHA, Rybelsus, SX-ONE MICROKNIFE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error